Prognostic and predictive factors in breast cancer patients
Mgr. Zuzana Šporiková; MUDr. Vladimíra Koudeláková; MUDr. Marián Hajdúch, Ph.D.
Ústav molekulární a translační medicíny LF UP, Olomouc
Current oncology is mainly focused towards the search of novel prognostic and predictive biomarkers, new therapeutics and therapeutic strategies leading to the development of personalized medicine. Current diagnostics of breast cancer uses the estrogen, progesterone and HER2 expression for prediction of endocrine and anti-HER2 therapy response and prognosis determining. Recently, BRCA1 and BRCA2 mutation testing for prediction of response to PARP inhibitors was introduced into clinical practice. In last decade, a number of biomarkers have been identified, however, they must be clinically validated by independent prospective study. The properly validated biomarkers have huge significance in current personalized oncology.
prognostic markers, predictive markers, breast cancer, ER, PR, HER2
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...